株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

胃腸疾患治療薬の世界市場:2016~2020年

Global Gastrointestinal Therapeutics Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 373833
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
胃腸疾患治療薬の世界市場:2016~2020年 Global Gastrointestinal Therapeutics Market 2016-2020
出版日: 2016年09月30日 ページ情報: 英文 102 Pages
概要

胃腸疾患には、消化管に影響を及ぼす機能的疾患と運動性疾患があります。世界の胃腸疾患治療薬市場は、2016~2020年にかけCAGR6.5%で拡大すると予測されています。

当レポートでは、世界の胃腸疾患治療薬市場について調査し、市場の現況と成長見通し、市場規模、セグメント別動向、地域別動向、および主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 パイプラインポートフォリオ

第6章 市況

  • 世界市場

第7章 疾患別市場セグメンテーション

第8章 世界のIBD治療薬市場

  • 潰瘍性大腸炎
  • クローン病
  • 分子タイプ別セグメンテーション

第9章 世界のIBS治療薬市場

第10章 世界の胃腸疾患OTC役市場

第11章 地域別セグメンテーション

  • 地域別市場
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第12章 市場促進因子

  • 生物製剤の消費増大
  • 後期段階分子の一時的承認
  • 革新的技術を用いた新規治療薬の開発
  • 診断ツールの改良が治療を求める人々を増加させる

第13章 促進因子の影響

第14章 市場の課題

  • OTC薬の消費増大
  • IBDおよびIBSの未知の病因
  • 開発中および上市済の薬剤の中止

第15章 促進因子と課題の影響

第16章 市場動向

第17章 ベンダー環境

  • 競合シナリオ
  • その他の注目すべきベンダー

第18章 主要ベンダー分析

  • AbbVie
  • Johnson & Johnson
  • 武田薬品工業株式会社
  • Allergan
  • UCB

第19章 付録

第20章 Technavioについて

図表
  • Exhibit 01:Product offerings
  • Exhibit 02:Global gastrointestinal therapeutics market: Key buying criteria 2015
  • Exhibit 03:Global gastrointestinal therapeutics market: Key customer segments
  • Exhibit 04:Global ulcerative colitis therapeutics market: Pipeline portfolio
  • Exhibit 05:Global Crohn's disease therapeutics market: Pipeline portfolio
  • Exhibit 06:Global IBS therapeutics market: Pipeline portfolio
  • Exhibit 07:Global gastrointestinal therapeutics market snapshot: Developed and emerging markets 2015
  • Exhibit 08:Global gastrointestinal therapeutics market: Factors affecting growth 2015 and 2020
  • Exhibit 09:Approval and patent expiries of top selling biologics
  • Exhibit 10:Global gastrointestinal therapeutics market 2016-2020 ($ billions)
  • Exhibit 11:Global gastrointestinal disorder therapeutics market segmentation: Growth cycle analysis
  • Exhibit 12:Five forces analysis
  • Exhibit 13:Global gastrointestinal therapeutics market by disease type: Revenue share 2015
  • Exhibit 14:Global gastrointestinal therapeutics market by disease type: Growth lifecycle analysis
  • Exhibit 15:Global gastrointestinal therapeutics market by disease type 2015-2020
  • Exhibit 16:Global IBD therapeutics market by type: Revenue share 2015
  • Exhibit 17:Global IBD therapeutics market by type 2015-2020
  • Exhibit 18:Global IBD therapeutics market segmentation: Growth lifecycle analysis
  • Exhibit 19:Global ulcerative colitis drugs market 2015-2020 ($ billions)
  • Exhibit 20:Global Crohn's disease drugs market 2015-2020 ($ billions)
  • Exhibit 21:Global IBD therapeutics market by molecule type 2015
  • Exhibit 22:Biologics in global IBD therapeutics market 2015-2020 ($ billions)
  • Exhibit 23:Small molecules in global IBD therapeutics market 2015-2020 ($ billions)
  • Exhibit 24:Global IBS therapeutics market 2015-2020 ($ billions)
  • Exhibit 25:Drugs that underwent Rx-to-OTC switch in the US
  • Exhibit 26:Global gastrointestinal OTC drugs market 2015-2020 ($ billions)
  • Exhibit 27:Global gastrointestinal therapeutics market by geography 2015-2020
  • Exhibit 28:Global gastrointestinal therapeutics market by geography 2015 and 2020
  • Exhibit 29:Global gastrointestinal therapeutics market by geography 2015-2020 ($ billions)
  • Exhibit 30:Global gastrointestinal therapeutics market by geography: Market share 2015
  • Exhibit 31:Global gastrointestinal therapeutics market by geography: Disease type 2015
  • Exhibit 32:Global gastrointestinal therapeutics market by geography: Market growth lifecycle analysis 2015
  • Exhibit 33:Global gastrointestinal therapeutics market by country: Revenue and growth rate analysis
  • Exhibit 34:Opportunity analysis of gastrointestinal therapeutics market in Americas
  • Exhibit 35:Gastrointestinal therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 36:Opportunity analysis of gastrointestinal therapeutics market in EMEA
  • Exhibit 37:Gastrointestinal therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 38:Opportunity analysis of gastrointestinal therapeutics market in APAC
  • Exhibit 39:Gastrointestinal therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 40:Impact of drivers and challenges on global gastrointestinal therapeutics market
  • Exhibit 41:Biologics for IBD: market share 2012-2022
  • Exhibit 42:Few biologics under development for gastrointestinal disorders
  • Exhibit 43:Impact of drivers
  • Exhibit 44:Rx-to-OTC switch: Promoters and inhibitors
  • Exhibit 45:Gastrointestinal therapeutics discontinued from development or market
  • Exhibit 46:Impact of drivers and challenges
  • Exhibit 47:Global gastrointestinal therapeutics market: Impact assessment of key trends
  • Exhibit 48:Gastrointestinal therapeutics with patient assistance programs in US
  • Exhibit 49:Biosimilars under development for gastrointestinal disorders
  • Exhibit 50:Regenerative medicines for IBD under development
  • Exhibit 51:Key vendors ranking 2015
  • Exhibit 52:Key vendors: Geographical presence
  • Exhibit 53:Market vendors: Competitive scenario 2015-2020
  • Exhibit 54:AbbVie: Profile
  • Exhibit 55:AbbVie: Strength analysis
  • Exhibit 56:AbbVie: Growth strategy matrix
  • Exhibit 57:AbbVie: Opportunity assessment
  • Exhibit 58:AbbVie: YoY growth and revenue of HUMIRA 2012-2014 ($ billions)
  • Exhibit 59:Johnson & Johnson: Profile
  • Exhibit 60:Johnson & Johnson: Strength analysis
  • Exhibit 61:Johnson & Johnson: Growth strategy matrix
  • Exhibit 62:Johnson & Johnson: Opportunity assessment
  • Exhibit 63:Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
  • Exhibit 64:Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
  • Exhibit 65:Takeda: Profile
  • Exhibit 66:Takeda: Strength analysis
  • Exhibit 67:Takeda: Growth strategy matrix
  • Exhibit 68:Takeda: Opportunity assessment
  • Exhibit 69:Allergan: Profile
  • Exhibit 70:Allergan: Strength analysis
  • Exhibit 71:Allergan: Growth strategy matrix
  • Exhibit 72:Allergan: Opportunity assessment
  • Exhibit 73:Allergan: Revenue of gastrointestinal therapeutics 2015 ($ millions)
  • Exhibit 74:UCB: Profile
  • Exhibit 75:UCB: Strength analysis
  • Exhibit 76:UCB: Growth strategy matrix
  • Exhibit 77:UCB: Opportunity assessment
目次
Product Code: IRTNTR10476

About Gastrointestinal Disorders

Gastrointestinal disorders include both functional and motility disorders affecting the gastrointestinal tract. Functional disorders involve an abnormality in the working of the gastrointestinal tract. They are the most common type of disorders and present with disturbances in motility, visceral hypersensitivity, changes in the mucosal and immune function, variations in central nervous system processing, and altered gut microbiota. Motility disorders are characterized by changes in the movement of the gastrointestinal tract and the transfer of its contents. Some of the most common gastrointestinal functional and motility disorders include IBS, GERD, Crohn's disease, ulcerative colitis, and peptic ulcers.

Technavio's analysts forecast the global gastrointestinal therapeutics market to grow at a CAGR of 6.5% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global gastrointestinal therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various gastrointestinal disorders including IBD, and irritable bowel syndrome (IBS).

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Gastrointestinal Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Johnson & Johnson
  • Takeda
  • Allergan
  • UCB

Other Prominent Vendors

  • 4SC
  • Ajinomoto Pharmaceuticals
  • Alfa Wassermann
  • Alizyme
  • Amgen
  • Anterogen
  • Ardelyx
  • Arena Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Astellas Pharma
  • Avaxia Biologics
  • Biogen Idec
  • BioLineRx
  • Celgene
  • ChemoCentryx
  • Cosmo Pharmaceuticals
  • Drais Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Enlivex Therapeutics
  • F. Hoffmann-La Roche
  • Ferring Pharmaceuticals
  • FF Pharma
  • Galapagos
  • Gilead Sciences
  • GlaxoSmithKline
  • Hutchison Medi Pharma
  • Immune Pharmaceuticals
  • InDex Pharmaceuticals
  • Ironwood Pharmaceuticals
  • Kaken Pharmaceutical
  • Kang Stem Biotech
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • Lipid Therapeutics
  • Meda
  • Merck
  • Mesoblast
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Morphotek
  • Neovacs
  • Nestle
  • Norgine
  • Novartis
  • Ono Pharmaceutical
  • Pfizer
  • Procter & Gamble
  • Qu Biologics
  • Receptos
  • RedHill Biopharma
  • Salix Pharmaceuticals
  • Shield Therapeutics
  • Sterna Biologicals
  • Synergy Pharmaceuticals
  • Synthetic Biologics
  • TiGenix
  • Tillotts Pharma
  • TopiVert
  • TSD Japan
  • Zeria Pharmaceutical

Market driver

  • Tentative approval of late stage molecules
  • For a full, detailed list, view our report

Market challenge

  • Discontinuation of drugs under development and from the market
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01:Executive summary

  • Highlights

PART 02:Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03:Market research methodology

  • Research methodology
  • Economic indicators

PART 04:Introduction

  • Key market highlights

PART 05:Pipeline portfolio

  • Ulcerative colitis
  • Crohn's disease
  • IBS

PART 06:Market landscape

  • Global gastrointestinal therapeutics market

PART 07:Market segmentation by disease type

  • Overview

PART 08:Global IBD therapeutics market

  • Global ulcerative colitis drugs market
  • Global Crohn's disease drugs market
  • Market segmentation by molecule type

PART 09:Global IBS therapeutics market

PART 10:Global gastrointestinal OTC drugs market

PART 11:Geographical segmentation

  • Global gastrointestinal therapeutics market by geography 2015-2020
  • Gastrointestinal therapeutics market in Americas
  • Gastrointestinal therapeutics market in EMEA
  • Gastrointestinal therapeutics market in APAC

PART 12:Market drivers

  • Increasing consumption of biologics
  • Tentative approval of late stage molecules
  • Development of novel therapies using innovative technologies
  • Improved diagnostic tools increasing the treatment-seeking population

PART 13:Impact of drivers

PART 14:Market challenges

  • Increased consumption of OTC medications
  • Unknown etiology of IBD and IBS
  • Discontinuation of drugs under development and from the market

PART 15:Impact of drivers and challenges

PART 16:Market trends

  • Patient assistance programs
  • Emergence of biosimilars
  • Rise in self-medication
  • Focus on regenerative medicines
  • Strategic alliances and M&A

PART 17:Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 18:Key vendor analysis

  • AbbVie
  • Johnson & Johnson
  • Takeda
  • Allergan
  • UCB

PART 19:Appendix

  • List of abbreviations

PART 20:Explore Technavio

Back to Top